A C‐Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti‐Psoriatic Activity via Microneedle Delivery
- 1Lingang Laboratory Shanghai China
- 2School of Physical Science and Technology ShanghaiTech University Shanghai China
- 3School of Life Science and Technology ShanghaiTech University Shanghai China
Abstract
Psoriasis is a chronic inflammatory disorder characterized by immune dysregulation and epidermal hyperplasia. Cordycepin, a natural adenosine analogue from traditional Chinese medicine Cordyceps militaris, possesses broad anti‑inflammatory and immunomodulatory properties, but its poor metabolic stability limits clinical use. Herein, 22 cordycepin derivatives for anti‐psoriasis were designed and synthesized. Among them, CPD3a, featuring a stable C─C glycosidic bond, exhibited potent anti‑inflammatory activity, high metabolic stability, and high resistance to in vivo metabolic deamination. CPD3a was formulated into a microneedle array (CPD3a‐MN) for the topical treatment of psoriasis. In a psoriasis‐like mouse model, CPD3a‐MN exhibited potent, dose‐dependent efficacy, significantly reducing pathological symptoms, ameliorating epidermal hyperplasia, and suppressing systemic inflammation. Meanwhile, CPD3a‐MN rebalanced systemic immunity by suppressing splenic neutrophils and inflammatory dendritic cells while increasing regulatory T cells and M2 macrophages. Activation of adenosine monophosphate‐activated protein kinase (AMPK)/nuclear factor erythroid 2‐related factor 2 (NRF2) pathway and a marked antioxidant effect were also observed following CPD3a‐MN treatment. Transcriptomic analysis demonstrated that CPD3a‐MN modulated the psoriatic transcriptome, suppressing interleukin‐17 (IL‐17)/nuclear factor‐kappa B (NF‐κB)‐driven inflammatory networks and concurrently activating genes involved in keratinocyte differentiation and epidermal barrier restoration. Moreover, CPD3a‐MN was well‑tolerated, with good biocompatibility. Collectively, CPD3a represents a superior therapeutic alternative to cordycepin for topical psoriasis treatment.
Related
- Cordycepin Regulates the Nrf2/Hmox1 Signaling Pathway to Inhibit Ferroptosis and Improve AKI‐CKD
- Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance
- A smart photothermal microneedle system for dual-targeted therapy of osteoarthritis via MMPs inhibition
- Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
- Oral lipid prodrug V2043 (1-O-octadecyl-2-O-benzyl-sn-glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection
BibTeX
@article{pan2026cnucleoside,
title = {{A C‐Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti‐Psoriatic Activity via Microneedle Delivery}},
author = {Wenfang Pan and Xinyue Shao and Yuanchen Zhong and Xujie Sun and Lixuan Yin and Zongyan He and Tianqun Lang and Yuanchao Xie},
journal = {Advanced Science},
year = {2026},
month = aug,
doi = {10.1002/advs.77012},
url = {https://doi.org/10.1002/advs.77012},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A C‐Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti‐Psoriatic Activity via Microneedle Delivery
AU - Wenfang Pan
AU - Xinyue Shao
AU - Yuanchen Zhong
AU - Xujie Sun
AU - Lixuan Yin
AU - Zongyan He
AU - Tianqun Lang
AU - Yuanchao Xie
PY - 2026
DA - 2026/08/05
JO - Advanced Science
DO - 10.1002/advs.77012
UR - https://doi.org/10.1002/advs.77012
AB - Psoriasis is a chronic inflammatory disorder characterized by immune dysregulation and epidermal hyperplasia. Cordycepin, a natural adenosine analogue from traditional Chinese medicine Cordyceps militaris, possesses broad anti‑inflammatory and immunomodulatory properties, but its poor metabolic stability limits clinical use. Herein, 22 cordycepin derivatives for anti‐psoriasis were designed and synthesized. Among them, CPD3a, featuring a stable C─C glycosidic bond, exhibited potent anti‑inflammatory activity, high metabolic stability, and high resistance to in vivo metabolic deamination. CPD3a was formulated into a microneedle array (CPD3a‐MN) for the topical treatment of psoriasis. In a psoriasis‐like mouse model, CPD3a‐MN exhibited potent, dose‐dependent efficacy, significantly reducing pathological symptoms, ameliorating epidermal hyperplasia, and suppressing systemic inflammation. Meanwhile, CPD3a‐MN rebalanced systemic immunity by suppressing splenic neutrophils and inflammatory dendritic cells while increasing regulatory T cells and M2 macrophages. Activation of adenosine monophosphate‐activated protein kinase (AMPK)/nuclear factor erythroid 2‐related factor 2 (NRF2) pathway and a marked antioxidant effect were also observed following CPD3a‐MN treatment. Transcriptomic analysis demonstrated that CPD3a‐MN modulated the psoriatic transcriptome, suppressing interleukin‐17 (IL‐17)/nuclear factor‐kappa B (NF‐κB)‐driven inflammatory networks and concurrently activating genes involved in keratinocyte differentiation and epidermal barrier restoration. Moreover, CPD3a‐MN was well‑tolerated, with good biocompatibility. Collectively, CPD3a represents a superior therapeutic alternative to cordycepin for topical psoriasis treatment.
SN - 2198-3844
ER -